Stelo Becomes the First Over-the-Counter Glucose Biosensor in the U.S.

1 minute read

March 6, 2024

1 minute read

March 6, 2024

On March 5, 2024, Dexcom, Inc. announced that the FDA has cleared Stelo to become the first over-the-counter glucose biosensor in the United States.

Stelo, which is indicated for persons 18 and older, allows people with type 2 diabetes to benefit from continuous glucose monitoring (CGM) technology.

What is Stelo?

Stelo will be the first glucose biosensor in the U.S. cleared for use without a prescription.

Stelo is a compact, wearable sensor that is placed on the back of the upper arm and sends glucose data directly to the user’s smartphone.

CGM technology enables individuals with diabetes to better understand how different diets and activities affect their blood-sugar levels.

When will Stelo be available?

Stelo will be available for purchase online without a prescription beginning in summer 2024.

To learn more and verify eligibility for Dexcom G7, visit https://www.dexcom.com/en-us/stelo.

Medtronic Receives FDA Clearance for Smart MDI System with New InPen App

Big Changes to Medicare Part D in 2025: What You Need to Know

Author

Daniel Trecroci

Dan has written about diabetes for more than 20 years. He was one of Diabetes Health's first recruits, and throughout his 10 + years as Managing Editor he wrote/published thousands of articles and helped establish Diabetes Health as the premiere resource for people with diabetes. He later became the Content Manager for OneTouchGold—Johnson & Johnson/LifeScan’s official digital publication for its metering-technology customers. Under his leadership, OneTouchGold received the Web Marketing Association’s award for “Best Health & Wellness" web site. Dan has also written for the Diabetes Research Institute, dLife, diaTribe, Healthline, CareDx, Pendulum Therapeutics, and Hero Bread.